Φορτώνει......
4CPS-166 Switching to alemtuzumab in patients with relapsing remitting multiple sclerosis
BACKGROUND: Alemtuzumab is a monoclonal antibody directed against the CD52 antigen on T- and B-lymphocytes indicated in adult patients with relapsing remitting multiple sclerosis (RRMS). PURPOSE: To assess safety, reason for switching, compliance with the protocol and with the criteria for use. MATE...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Eur J Hosp Pharm |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMJ Group
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535247/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.257 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|